Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

255 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Screening and monitoring of the BTKC481S mutation in a real-world cohort of patients with relapsed/refractory chronic lymphocytic leukaemia during ibrutinib therapy.
Bödör C, Kotmayer L, László T, Takács F, Barna G, Kiss R, Sebestyén E, Nagy T, Hegyi LL, Mikala G, Fekete S, Farkas P, Balogh A, Masszi T, Demeter J, Weisinger J, Alizadeh H, Kajtár B, Kohl Z, Szász R, Gergely L, Gurbity Pálfi T, Sulák A, Kollár B, Egyed M, Plander M, Rejtő L, Szerafin L, Ilonczai P, Tamáska P, Pettendi P, Lévai D, Schneider T, Sebestyén A, Csermely P, Matolcsy A, Mátrai Z, Alpár D. Bödör C, et al. Among authors: demeter j. Br J Haematol. 2021 Jul;194(2):355-364. doi: 10.1111/bjh.17502. Epub 2021 May 21. Br J Haematol. 2021. PMID: 34019713
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry.
Takács F, Kotmayer L, Czeti Á, Szalóki G, László T, Mikala G, Márk Á, Masszi A, Farkas P, Plander M, Weisinger J, Demeter J, Fekete S, Szerafin L, Deák BM, Szaleczky E, Sulák A, Borbényi Z, Barna G. Takács F, et al. Among authors: demeter j. Pathol Oncol Res. 2022 Sep 21;28:1610659. doi: 10.3389/pore.2022.1610659. eCollection 2022. Pathol Oncol Res. 2022. PMID: 36213161 Free PMC article.
Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms.
Mózes R, Gángó A, Sulák A, Vida L, Reiniger L, Timár B, Krenács T, Alizadeh H, Masszi T, Gaál-Weisinger J, Demeter J, Csomor J, Matolcsy A, Kajtár B, Bödör C. Mózes R, et al. Among authors: demeter j. Pathology. 2019 Apr;51(3):301-307. doi: 10.1016/j.pathol.2018.11.007. Epub 2018 Dec 31. Pathology. 2019. PMID: 30606612
[TP53 mutation analysis in chronic lymphocytic leukaemia].
Fésüs V, Marosvári D, Kajtár B, Király PA, Demeter J, Gurbity Pálfi T, Egyed M, Plander M, Farkas P, Mátrai Z, Matolcsy A, Bödör C. Fésüs V, et al. Among authors: demeter j. Orv Hetil. 2017 Feb;158(6):220-228. doi: 10.1556/650.2017.30656. Orv Hetil. 2017. PMID: 28166664 Hungarian.
Quantitative assessment of JAK2 V617F and CALR mutations in Philadelphia negative myeloproliferative neoplasms.
Gángó A, Mózes R, Boha Z, Kajtár B, Timár B, Király PA, Kiss R, Fésüs V, Nagy N, Demeter J, Körösmezey G, Borbényi Z, Marton I, Szőke A, Masszi T, Farkas P, Várkonyi J, Plander M, Pósfai É, Egyed M, Pál K, Radványi G, Hamed A, Csomor J, Matolcsy A, Alpár D, Bödör C. Gángó A, et al. Among authors: demeter j. Leuk Res. 2018 Feb;65:42-48. doi: 10.1016/j.leukres.2017.12.005. Epub 2018 Jan 2. Leuk Res. 2018. PMID: 29306106
255 results